T CELL RECEPTOR BINDING TO ALWGPDPAAA, DERIVED FROM HUMAN PRE-PRO INSULIN (PPI) PROTEIN
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Jun 14, 2016
filing date -
Dec 18, 2013
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention provides a T cell receptor (TCR) having the property of binding to ALWGPDPAAA (derived from human pre-pro insulin (PPI) protein) HLA-A*02 complex and comprising a TCR alpha chain variable domain and a TCR beta chain variable domain. Also provided are nucleic acids encoding the TCR and cells engineered to present the TCR. Therapeutic agents based on TCRs of the invention can be used for the purpose of delivering immunosuppressive agents to beta cells in order to prevent their destruction by CD8+ T cells.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully